2015-2016 Synagis® Seasonal Respiratory Syncytial Virus Enrollment Form

CareFirst The CareFirst BlueCross BlueShield family of health care plans

Fax: (800) 323-2445 | **Email:** customerservicefax@caremark.com | **Phone:** (800) 237-2767

6 Simple step to submitting a referral

1 PATIENT INFORMATION

(Complete the following or include demographic sheet)

Patient Name: _____
Address: _____
City, State, Zip: _____
Primary Phone: _____ ☐Home ☐Cell ☐Work
Alternate Phone: _____ ☐Home ☐Cell ☐Work
DOB: _____ Gender: ☐Male ☐Female
E-mail: _____
Last Four of SS #: _____ Primary Language: _____

2 PRESCRIPTION INFORMATION

Prescriber's Name: _____
State License #: _____ NPI # _____
DEA #: _____
Group or Hospital: _____
Address: _____
City, State, Zip: _____
Phone: _____ Fax: _____
Contact Person: _____ Phone: _____

3 INSURANCE INFORMATION

Please fax copy of prescription and insurance cards with this form if available (front and back).

Prescription Card:	Name of Insurer:		ID#:		BIN:		PCN:	Group:	
Medical Insurance:	Subscriber:		ID#:		Name of Insurer:			Phone:	
Secondary Insurance:	Subscriber:		ID#:		Name of Insurer:			Phone:	

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Expected date of first injection: _____

Ship to: ☐ Prescriber Office ☐ Patient Home ☐ Other: _____

☐ Yes, CVS Caremark is to coordinate home health nurse visit for injection ☐ No coordination If yes, agency of choice: _____

Diagnosis (ICD-9 or ICD-10)

☐ <24 wks of gestation (765.21) ☐ 24 wks of gestation (765.22) ☐ 25-26 wks of gestation (765.23) ☐ 27-28 wks of gestation (765.24)
☐ 29-30 wks of gestation (765.25) ☐ 31-32 wks of gestation (765.26) ☐ 33-34 wks of gestation (765.27) ☐ 35-36 wks of gestation (765.28)
☐ 37 wks + of gestation (765.29) ☐ Congenital Heart Disease (Specify ICD-9): _____ ☐ Other: _____
☐ Chronic Respiratory Disease arising in the perinatal period (CLD) (770.7) ☐ Congenital Abnormality of Respiratory System (748.3-748.4)

Patient's gestational age (Required) weeks days

Current weight: g/kg/lbs Date recorded: / /

Multiple births: ☐ No ☐ Yes Enter names of Synagis candidates (submit separate enrollment forms):

NICU history: ☐ No ☐ Yes If yes, NICU name & include NICU summary:

Allergies: Medical conditions not listed below:

Clinical Conditions	2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines
Chronic Lung Disease (CLD)	* CLD of prematurely defined as gestational age ≤ 31 weeks, 6 days, AND requirement for 21% oxygen for at least the first 28 days after birth ☐ <12 months of age w CLD * ☐ 12-24 months of age w CLD * AND continues to require medical support* during the 6-month period before second RSV season AND ☐ Supplemental oxygen (dates) _____ ☐ Diuretic therapy (drugs/dates) _____ ☐ Chronic corticosteroids (drugs/date) _____ ☐ Bronchodilators (drugs/dates) _____
Congenital Heart Disease (CHD)	☐ <12 months of age at start of season with hemodynamically significant CHD such as: ☐ Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (Meds/dates) _____ (Surgery date) _____ ☐ Moderate to severe pulmonary hypertension ☐ Other: describe _____ ☐ <24 months of age undergoing cardiac transplantation during the RSV season (date) ☐ Cyanotic Heart Disease; Diagnosis: _____
Airway/Neuromuscular Conditions	☐ <12 months of age at start of season and compromised handling of secretions AND due to: ☐ Significant abnormality of the airway (attach clinical notes) ☐ Neuromuscular condition (attach clinical notes)
Prematurity	☐ ≤ GA 28 wks, 6 days AND < 12 months at start of season
Other medical history or conditions	☐ Other medical history (describe)

5 PRESCRIPTION INFORMATION

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
☐ Synagis® (palivizumab) and ancillary supplies	☐ 50 and/or 100mg vials	☐ Inject 15mg/kg IM one time per month ☐ Other: _____	QS to achieve 15mg/kg dose	
☐ Epinephrine and ancillary supplies **	1:1000 amp	Inject 0.01 mg/kg subcutaneously as directed for anaphylaxis		

*This prescription also covers ancillary supplies (syringes, needles, etc.) for administration as needed.
**When required for home/injection clinic administration

☐ Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

6

PHYSICIAN SIGNATURE REQUIRED

X _____ (Date)
DISPENSE AS WRITTEN

X _____ (Date)
PRODUCT SUBSTITUTION PERMITTED

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. Hepatitis C 022514

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc.
CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association.
® Registered trademark of CareFirst of Maryland, Inc.